References
- Hely MA , MorrisJG, ReidWG, TrafficanteR. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord., 20(2), 190–199 (2005).
- Fox SH , KatzenschlagerR, LimSYet al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 33(8), 1248–1266 (2018).
- Alvir JM , LiebermanJA, SaffermanAZ, SchwimmerJL, SchaafJA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med., 329(3), 162–167 (1993).
- Postma JU , Van TilburgW. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J. Am. Geriatr. Soc., 23(5), 212–215 (1975).
- Vecsei L , SzalardyL, FulopF, ToldiJ. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov., 12(1), 64–82 (2013).
- Di Paolo T . Anti-dyskinetic activity in non-human Parkinsonian primates of AV 101 a prodrug acting as a NMDA receptor glycine antagonist. J. Neurol. Clin. Neurosci., 3, 19 (2019).
- ClinicalTrials.gov. NCT04147949 . AV-101 (L-4-chlorokynurenine) in Parkinson’s disease subjects with levodopa-induced dyskinesia (2021). https://clinicaltrials.gov/ct2/show/NCT04147949
- Iderberg H , McCrearyAC, VarneyMAet al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat. Exp. Neurol., 271, 335–350 (2015).
- McCreary AC , VarneyMA, Newman-TancrediA. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements. Neuropharmacology, 105, 651–660 (2016).
- Fisher R , HikimaA, MorrisRet al. The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-Parkinsonian-like effects in MPTP-treated marmosets. Neuropharmacology, 167, 107997 (2020).
- Depoortere R , JohnstonTH, FoxSH, BrotchieJM, Newman-TancrediA. The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Park. Relat. Disord., 78, 151–157 (2020).
- Kannari K , KurahashiK, TomiyamaMet al. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease]. No To Shinkei, 54(2), 133–137 (2002).
- Kleedorfer B , LeesAJ, SternGM. Buspirone in the treatment of levodopa induced dyskinesias. J. Neurol. Neurosurg. Psychiatry, 54(4), 376–377 (1991).
- Goetz CG , DamierP, HickingCet al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov. Disord., 22(2), 179–186 (2007).
- Neurolixis . 30 november 2021 - First patient dosed in clinical trial of NLX-112 for dyskinesia in Parkinson’s disease (2021). https://www.neurolixis.com/en/news.html
- Tison F , KeywoodC, WakefieldMet al. A phase IIA trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson’s disease. Mov. Disord., 31(9), 1373–1380 (2016).
- ClinicalTrials.gov. NCT04857359 . Dipraglurant (ADX48621) for the treatment of patients with Parkinson’s disease receiving levodopa-based therapy (2021). https://clinicaltrials.gov/ct2/show/NCT04857359?term=dipraglurant&draw=2&rank=3
- ClinicalTrials.gov. NCT05116813 . Open-label safety study of dipraglurant (ADX48621) in patients with Parkinson’s disease receiving levodopa-based therapy (2021). https://clinicaltrials.gov/ct2/show/NCT05116813?term=dipraglurant&draw=2&rank=1
- Schipper J , TulpMT, SijbesmaH. Neurochemical profile of eltoprazine. Drug Metabol. Drug Interact., 8(1–2), 85–114 (1990).
- Svenningsson P , RosenbladC, AfEdholm Arvidsson Ket al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain, 138(Pt 4), 963–973 (2015).
- ClinicalTrials.gov. NCT02439125 . A study of efficacy and safety of eltoprazine HCl for treating levodopa-induced dyskinesia in Parkinson’s disease patients. https://clinicaltrials.gov/ct2/show/NCT02439125?term=NCT02439125&draw=2&rank=1
- Schuster S , NadjarA, GuoJTet al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson’s disease. J. Neurosci., 28(17), 4311–4316 (2008).
- Tison F , Negre-PagesL, MeissnerWGet al. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Park. Relat. Disord., 19(4), 416–421 (2013).
- ClinicalTrials.gov. NCT04064294 . Preventing levodopa induced dyskinesia in Parkinson’s disease with HMG-CoA reductase inhibitors (STAT-PD). https://clinicaltrials.gov/ct2/show/NCT04064294
- McFarthing K , PrakashN, SimuniT. Clinical trial highlights - dyskinesia. J. Parkinsons Dis., 9(3), 449–465 (2019).
- Huot P , FoxSH, BrotchieJM. The serotonergic system in Parkinson’s disease. Prog. Neurobiol., 95(2), 163–212 (2011).
- Jackson MJ , Al-BarghouthyG, PearceRK, SmithL, HaganJJ, JennerP. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav., 79(3), 391–400 (2004).
- ClinicalTrials.gov. NCT03956979 . A study in Parkinson’s disease in patients with moderate to severe dyskinesia (ASTORIA). https://clinicaltrials.gov/ct2/show/NCT03956979
- ClinicalTrials.gov. NCT04377945 . Study in Parkinson’s disease patients with dyskinesia with combinations of JM-010 and its individual components (SHINE). https://clinicaltrials.gov/ct2/show/NCT04377945
- ClinicalTrials.gov. NCT02439203 . Efficacy and safety of JM-010 in PD with levodopa-induced dyskinesia (LID). https://clinicaltrials.gov/ct2/show/NCT02439203
- Waters S , SonessonC, SvenssonPet al. Preclinical pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)ethyl](Propyl)amine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson disease. J. Pharmacol. Exp. Ther., 374(1), 113–125 (2020).
- Svenningsson P , JohanssonA, NyholmDet al. Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia – a phase 1B trial. NPJ Parkinsons Dis., 4, 35 (2018).
- ClinicalTrials.gov. NCT03368170 . Efficacy and tolerability of IRL790 in Parkinson’s disease dyskinesia. https://clinicaltrials.gov/ct2/show/NCT03368170
- ClinicalTrials.gov. NCT04435431 . A clinical study of mesdopetam in patients with Parkinson’s disease experiencing levodopa induced dyskinesia. https://clinicaltrials.gov/ct2/show/NCT04435431
- Wu N , SongL, YangXX, WeiJL, LiuZG. [Effects of Chinese herbal medicine Tianqi Pingchan granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease]. Zhong Xi Yi Jie He Xue Bao, 10(9), 1018–1024 (2012).
- ClinicalTrials.gov. NCT04173845 . Double randomized and placebo controlled trail of tianqi pingchan granule to prevent levodopa-induced dyskinesia. https://clinicaltrials.gov/ct2/show/NCT04173845
- ClinicalTrials.gov. NCT04173832 . Clinical study on treatment of L-DOPA-induced dyskinesia with tianqi pingchan granule combined with amantadine. https://clinicaltrials.gov/ct2/show/NCT04173832
- ClinicalTrials.gov. NCT02617017 . Buspirone treatment of iatrogenic dyskinesias in advanced Parkinson’ disease (BUSPARK). https://clinicaltrials.gov/ct2/show/NCT02617017
- ClinicalTrials.gov. NCT02589340 . Buspirone, in combination with amantadine, for the treatment of levodopa-induced dyskinesia (BUS-PD). https://clinicaltrials.gov/ct2/show/NCT02589340
- Potts LF , ParkES, WooJMet al. Dual kappa-agonist/mu-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann. Neurol., 77(6), 930–941 (2015).
- Trevi Therapeutics . (2021). https://www.trevitherapeutics.com/pipeline/
- Johnston TH , GevaM, SteinerLet al. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov. Disord., 34(5), 708–716 (2019).
- ClinicalTrials.gov. NCT03922711 . A study to assess the safety and effectiveness of pridopidine compared to placebo in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. https://clinicaltrials.gov/ct2/show/NCT03922711
- Cotzias GC , Van WoertMH, SchifferLM. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 276(7), 374–379 (1967).